No abstract

No abstract

Gmelina arborea Roxb. (Family Verbenaceae) leaves have long been used in traditional medicine to cure a variety of medical conditions. The purpose of this study is to examine the methanol, hydro alcohol, aqueous, hexane, ethyl acetate, extracts of Gmelina arborea leaves through FTIR spectroscopy method. FTIR (Fourier transform infrared spectroscopy) is a quick and nondestructive analysis technique. FTIR was utilised on a spectrophotometer system and performed to the identification of the typical peak values and the functional groups of Gmelina arborea leaf extracts. The presence of various bio-active functional groups in each extract was verified by FTIR analysis.

Background Dietary and wholesome antioxidant rutin is considered advantageous due to its potential protective role for numerous diseases related to oxidative stress, high safety, cost-effectiveness, and extensive biological effects. The present study accounts for an expeditious method for the synthesis of silver nanoparticles (AgNPs) using rutin. Results The presence of AgNPs was affirmed by UV–visible spectroscopy at 425 nm, and FESEM and zeta sizer analysis revealed the average size of the AgNPs 80–85 nm and 160 d.nm, respectively. Zeta potential measurements (− 30.3 mV) showed that the AgNPs have reasonably good stability. Element mapping analysis of the AgNPs was confirmed by XRD and AFM, while FTIR spectra of the AgNPs showed the existence of functional groups. In the DPPH assay, highest radical scavenging activity of AgNPs, 86.95 ± 01.60%, was confirmed. The interaction of AgNPs with CT-DNA and HS-DNA was studied spectrophotometrically, and the data display a shift in the respective spectra. Furthermore, interaction with pBR322 DNA, λ DNA, CT-DNA, and HS-DNA was deliberated by a nicking assay that shows the physicochemical properties of AgNPs. Antibacterial activity was evaluated by the standard well-diffusion method against Escherichia coli and Staphylococcus aureus, and cytotoxicity was assessed against human WBCs by MTT assay. Conclusion As per this appraisal, it can be concluded that it is a cost-effective, simple, and eco-friendly tactic and such NPs are beneficial to improve therapeutics since the antioxidant, DNA interaction, antibacterial, and cytotoxic exploits offer a new horizon of euthenics.

IntroductionBuilding capacity to improve sex/gender knowledge and strengthen patient engagement in clinical trials requires training and support. The overall goal of this 2-year project is to refine, translate and evaluate two web-based open-access patient and investigator decision aids aimed to improve patient engagement partnerships in clinical trials.Methods and analysisTwo decision aids were designed in Phase 1 of this programme of research and this protocol describes a subsequent sequential phased approach to refine/translate (Phase 2A) and conduct alpha/usability (Phase 2B) and beta/field (Phase 3) testing. Decision aid development is guided by the International Patient Decision Aid Standards, User-Centred Design, Ottawa Decision-Support Framework and the Ottawa Model of Research Use. We have integrated patient-oriented research methods by engaging patient partners across all phases of our programme of research. Decision aids will first be refined and then translated to French (Phase 2A). Eight iterative cycles of semistructured interviews with 40 participants (20 patient partners and 20 investigators) will be conducted to determine usability (Phase 2B). A pragmatic pre/post pilot study design will then be implemented for field/beta testing using another purposive sample of 80 English-speaking and French-speaking participants (40 patients and 40 investigators). The samples are purposive to ensure an equal representation of English-speaking and French-speaking participants and an equal representation of men and women. Since sex and/or gender differences in utilisation and effectiveness of decision aids have not been previously reported, Phase 3 outcomes will be reported for the total sample and separately for men and women.Ethics and disseminationEthics approval has been granted from the University of Toronto (41109, 28 September 2021). Informed consent will be obtained from participants. Dissemination will include co-authored publications, conference presentations, educational national public forums, fact sheets/newsletters, social media sharing and videos/webinars.